Evidence map›Paper›PMID 38918748›Full record

ArticleBMC public health2024

Dynamics of HIV PrEP use and coverage during and after COVID-19 in Germany.

Daniel Schmidt, Yannick Duport, Christian Kollan, Ulrich Marcus, Sara Iannuzzi, Max von Kleist

Abstract read
In one paragraph

Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. [Monitoring of HIV pre-exposure prophylaxis in Germany based on statutory health insurance claims data].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniel SchmidtDepartment of Infectious Disease Epidemiology, Robert-Koch Institute, Berlin, Germany. SchmidtD@rki.de.
Yannick DuportProject Groups, Robert-Koch Institute, Berlin, Germany.
Christian KollanDepartment of Infectious Disease Epidemiology, Robert-Koch Institute, Berlin, Germany.
Ulrich MarcusDepartment of Infectious Disease Epidemiology, Robert-Koch Institute, Berlin, Germany.
Sara IannuzziProject Groups, Robert-Koch Institute, Berlin, Germany.
Max von KleistProject Groups, Robert-Koch Institute, Berlin, Germany. vkleist@zedat.fu-berlin.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPre-exposure prophylaxis (PrEP) with oral emtricitabine/tenofovir disoproxil (FTC/TDF) proved highly efficient in preventing HIV. Since 09/2019, FTC/TDF-PrEP is covered by health insurances in Germany, if prescribed by licensed specialists. However, methods to longitudinally monitor progress in PrEP implementation in Germany are lacking.

methodsUtilizing anonymous FTC/TDF prescription data from 2017-2021, we developed a mathematical model to disentangle HIV-treatment from PrEP prescriptions, as well as to translate PrEP prescriptions into number of PrEP users. We used the model to estimate past- and future PrEP uptake dynamics, to predict coverage of PrEP needs and to quantify the impact of COVID-19 on PrEP uptake on a national and regional level.

resultsWe identified significant (p<0.01) decelerating effects of the first- and second COVID-19-lockdown on PrEP uptake in 04/2020 and 12/2020. We estimated 26,159 (CI: 25,751-26,571) PrEP users by 12/2021, corresponding to 33% PrEP coverage of people in need. We projected 64,794 (CI: 62,956-66,557) PrEP users by 12/2030, corresponding to 81% PrEP coverage. We identified profound regional differences, with high PrEP coverage and uptake in metropoles and low coverage in more rural regions.

conclusionsOur approach presents a comprehensive solution to monitor and forecast PrEP implementation from anonymous data and highlighted that the COVID-19 pandemic significantly decelerated PrEP uptake in Germany. Moreover, slow PrEP uptake in rural areas indicate that structural barriers in PrEP care, education or information exist that may hamper the goal of ending the AIDS epidemic by 2030.

Indexed as

Anti-HIV AgentsCOVID-19HIV InfectionsPre-Exposure ProphylaxisAdultEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationFemaleGermanyHumansMaleModels, TheoreticalAnti-HIV AgentsEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationCOVID-19GermanyHIV-PrEP usersPharmaceutical prescription dataPrEP coveragePrEP need

Identifiers

PMID38918748
PMCPMC11197325

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.